Activin and TGF use diverging mitogenic signaling in advanced colon cancer
    
Yazarlar (10)
Jessica Bauer Türkiye
Prof. Dr. Özkan ÖZDEN Kafkas Üniversitesi, Türkiye
Naomi Akagi Türkiye
Timothy Carroll Türkiye
Daniel Principe Türkiye
Jonas Staudacher Türkiye
Martina Spehlman Türkiye
Lars Echman Türkiye
Paul Grippo Türkiye
Barbara Jung Türkiye
Makale Türü Açık Erişim Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı MOLECULAR CANCER
Dergi ISSN 1476-4598 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili İngilizce Basım Tarihi 10-2015
Cilt / Sayı / Sayfa 14 / 1 / 1–14 DOI 10.1186/s12943-015-0456-4
Makale Linki http://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0456-4
Özet
Understanding cell signaling pathways that contribute to metastatic colon cancer is critical to risk stratification in the era of personalized therapeutics. Here, we dissect the unique involvement of mitogenic pathways in a TGFβ or activin-induced metastatic phenotype of colon cancer. Mitogenic signaling/growth factor receptor status and p21 localization were correlated in primary colon cancers and intestinal tumors from either AOM/DSS treated ACVR2A (activin receptor 2) -/- or wild type mice. Colon cancer cell lines (+/- SMAD4) were interrogated for ligand-induced PI3K and MEK/ERK pathway activation and downstream protein/phospho-isoform expression/association after knockdown and pharmacologic inhibition of pathway members. EMT was assessed using epithelial/mesenchymal markers and migration assays. In primary colon cancers, loss of nuclear p21 correlated with upstream activation of activin/PI3K while nuclear p21 expression was associated with TGFβ/MEK/ERK pathway activation. Activin, but not TGFβ, led to PI3K activation via interaction of ACVR1B and p85 independent of SMAD4, resulting in p21 downregulation. In contrast, TGFβ increased p21 via MEK/ERK pathway through a SMAD4-dependent mechanism. While activin induced EMT via PI3K, TGFβ induced EMT via MEK/ERK activation. In vivo, loss of ACVR2A resulted in loss of pAkt, consistent with activin-dependent PI3K signaling. Although activin and TGFβ share growth suppressive SMAD signaling in colon cancer, they diverge in their SMAD4-independent pro-migratory signaling utilizing distinct mitogenic signaling pathways that affect EMT. p21 localization in colon cancer may determine a dominant activin versus TGFβ ligand signaling phenotype warranting further validation as a therapeutic biomarker prior to targeting TGFβ family receptors.
Anahtar Kelimeler
Colon cancer | Activin | TGF beta | PI3K | Mitogenic signaling | p21
BM Sürdürülebilir Kalkınma Amaçları
Atıf Sayıları
WoS 54
Activin and TGF use diverging mitogenic signaling in advanced colon cancer

Paylaş